Torrent Pharma

Torrent Pharma's revenue from operations rose 42 per cent Y-o-Y to ₹4,197 crore in Q4FY26 from ₹2,959 crore in Q4FY25

Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138

Torrent Pharma's Q4 profit dropped 22% as JB Pharma integration costs pushed up expenses, despite strong growth in semaglutide-led revenues

Torrent Group has entered the diagnostics sector with a 100,000 sq ft national reference lab in Navi Mumbai, marking a long-term push into high-end, specialised testing amid industry consolidation

Stocks to Watch today, Feb 16: From Ola Electric to Inox Green Energy, here are few stocks that will be on investors' radar

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Torrent Pharma Q3 revenue from operations increased 17.7 per cent year-on-year (Y-o-Y) to ₹3,251 crore from ₹2,762 crore in Q3FY25

Torrent Pharmaceuticals said the tenure of the instruments, along with the date of allotment and final maturity, will be determined at the time of issuance of NCDs

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Led by the India business and rest-of-the-world markets, the company reported a robust 14.3 per cent year-on-year (Y-o-Y) growth in revenues

Torrent Pharmaceuticals posted a 16% rise in Q2FY26 profit to Rs 591 crore, with double-digit growth across India, the US, and Brazil driving revenue higher.

Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd's proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in JB Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to the acquisition of shareholding by Torrent Pharmaceuticals Ltd (acquirer) in JB Chemicals & Pharmaceuticals Ltd (target) and the subsequent amalgamation of the target with the acquirer," the regulator said in a release. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. "The Commission approved the proposed combination subject to compliance with voluntary modifications offered by the parties (Torrent Pharmaceuticals Ltd and JB Chemicals & Pharmaceuticals Ltd)," it added. Torrent Pharmaceuticals is the ...

Analysts are optimistic on Torrent Pharma's growth after a solid Q1 FY26 report, with strong performance in Brazil and US generics despite currency volatility and German challenges

Torrent Pharmaceuticals on Monday said its consolidated net profit increased 20 per cent year-on-year to Rs 548 crore in the June quarter, driven by strong sales across markets, including India and the US. The drug firm reported a net profit of Rs 457 crore in the April-June quarter of the last fiscal. Revenue from operations rose to Rs 3,178 crore in the June quarter compared with Rs 2,859 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The drug maker said its India revenues rose by 11 per cent year-on-year to Rs 1,811 crore in the April-June period, led by outperformance in focus therapies. The US business revenues stood at Rs 308 crore in the June quarter, by 19 per cent year-on-year, it added. Similarly, revenue in Brazil rose by 11 per cent to Rs 218 crore, the company stated. Its sales in Germany were up 9 per cent year-on-year to Rs 308 crore in the June quarter against the same period last year. Shares of Torrent Pharma settled 0.75 per cent hi

Torrent Pharmaceuticals reports Rs 548 crore Q1 net profit, led by strong growth in India, the US, and Brazil, with chronic therapies and top brands driving momentum

Stocks to buy: Analyst at Angel One recommends Shyam Metalics and Torrent Pharma; Check target price, stop loss here

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & ...

Despite steep premium and short-term earnings dilution, analysts expect Torrent Pharma's acquisition of JB Chemicals to be value accretive in the medium term